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ABSTRACT
VEGFR1 rs9582036 and rs9554320 were previously reported the association 
with sunitinib progression-free survival (PFS) and overall survival (OS) in patients 
with metastatic renal cell carcinoma (mRCC). Hereafter, the association of both single 
nucleotide polymorphisms (SNPs) with PFS/OS was confirmed in two independent 
mRCC cohorts. The aim of the current study was to validate the associations of 
both SNPs with sunitinib outcome in three independent well-characterized cohorts 
(SUTOX, CCF and SOGUG) including 286 sunitinib-treated mRCC patients, as well as 
to perform a meta-analysis of current and published data combined. We found that 
rs9582036 and rs9554320 showed a significant association with sunitinib PFS in the 
CCF cohort (HR: 0.254, 95%CI: 0.092-0.703; P=0.008 and HR: 0.430, 95%CI: 0.200-
0.927; P=0.031, respectively). Patients with the variant genotype of rs9582036 and 
rs9554320 had a shorter median PFS. No significant association of both SNPs with 
sunitinib PFS or OS was detected in either the SUTOX or SOGUG cohort. After the 
combination of all available data into a meta-analysis, the association of both SNPs 
with sunitinib PFS or OS did not achieve the threshold for statistical significance. Our 
findings suggest that, although VEGFR1 rs9582036 and rs9554320 are involved in 
sunitinib therapy outcome, its clinical use as biomarkers for prediction of sunitinib 
outcome in mRCC patients is limited, due to inconsistent findings when analyzing all 
existing studies together.
INTRODUCTION
Renal cell carcinoma (RCC) is among the top 10 
most common malignancies in men world-wide [1]. There 
are several subtypes of RCC, but clear cell RCC represents 
80-85% of all cases [2]. Metastatic spread has occurred 
in 25-30% of patients by the time of initial diagnosis 
[3]. Surgical resection is curative in the majority of RCC 
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patients [4], but patients with advanced or metastatic 
renal cell carcinoma (mRCC) are candidate for systematic 
therapy [5].
Studies have shown that vascular endothelial growth 
factor (VEGF) is highly expressed in RCC, highlighting 
the fact that RCC is a VEGF-driven disease whose 
development is directly linked to VEGF overexpression 
and angiogenesis [6]. In recent years, targeted therapy 
including the VEGF-inibitor bevacizumab, VEGFR 
tyrosine kinase inhibitors (TKIs) or mammalian target 
of rapamycin (mTOR) inhibitors has largely replaced 
cytokine therapy. Sunitinib, an oral TKI inhibiting 
VEGFRs 1, 2, and 3, platelet-derived growth factor 
receptor (PDGFR) α and β, KIT, Fms-like tyrosine kinase 
3 receptor (FLT3), and the receptor encoded by the ret 
proto-oncogene (RET), has been approved by the Food 
and Drug Administration (FDA) in 2006 and became 
the first-line treatment for mRCC patients. The median 
progression-free survival (PFS) has improved considerably 
from 5 months with interferon-alpha to 11 months with 
sunitinib [7]. However, only 31% of the patients have 
complete or partial response and intrinsic resistance is 
observed in approximately 21% of the patients [7]. The 
most common adverse events of sunitinib treatment are 
leukopenia (78%), anemia (71%), thrombocytopenia 
(60%), diarrhea (53%), fatigue (51%), hypertension (24%) 
and hand-foot syndrome (20%) [7]. Most adverse events 
are of grade 1 or 2, and typically manageable with standard 
medical interventions, but 32% of the patients need dose 
reduction due to grade 3 or 4 adverse events [8]. Given 
the large inter-individual variability, the establishment 
of pharmacogenetic markers to predict the response to 
sunitinib treatment is a highly desirable goal [8, 9].
In recent years, several single nucleotide 
polymorphisms (SNPs) in VEGF pathway have been 
described the association with sunitinib outcome in mRCC 
patients [8, 10–15]. However, there is a lack of validated 
biomarker which could predict sunitinib outcome and 
guide individualized therapy. In 2014, Beuselinck et al. 
explored the association of the VEGFR1 rs9582036 A>C 
in 91 mRCC patients treated with sunitinib [16]. Patients 
with the CC-variant in rs9582036 A>C showed a lower 
response rate (0% vs. 46%) as well as a shorter PFS 
(10 vs. 18 months) and OS (14 vs. 31 months) compared 
to patients with an AC/AA genotype. Besides, Beuselinck 
et al. have reported that patients with the AA-variant in 
VEGFR1 rs9554320 C>A had a shorter PFS (12 vs. 21 
months) and OS (22 vs. 34 months) compared to patients 
with an AC/CC genotype [16]. After correction for 
covariates, rs9582036 remained significantly associated 
with OS (HR: 0.25; 95%CI: 0.08-0.80; P=0.008) and 
rs9554320 with PFS (HR: 0.37; 95%CI: 0.18-0.76; 
P=0.005) [16]. Hereafter, Dornbusch et al. investigated 
the associations of both SNPs in a cohort of 121 sunitinib-
treated mRCC patients but found inconsistent results. It 
was confirmed that patients with a CC-variant genotype 
of VEGFR1 rs9582036 had a shorter OS compared to 
patients with an AA/AC genotype (16 vs 42 months; 
HR: 0.24; 95%CI: 0.10-0.60; P= 0.002), but could not 
replicate the association of rs9582036 with PFS or 
rs9554320 with PFS and OS [17]. Lately, Beuselinck 
et al. successfully validated the association of both SNPs 
in another independent validation cohort of 69 mRCC 
patients treated with sunitinib. After pooling patients from 
the discovery and validation cohort, both SNPs remained 
significant association with PFS and OS [18].
Located in the intron region, both SNPs may cause 
a change of VEGFR1 expression. It has been reported 
that minor allele of rs9582036 reduces transcriptional 
activity and decreases VEGFR1 expression [19]. But 
this correlation has not yet been validated by either other 
researchers or Beuselinck et al [18]. So far, it is unclear 
of the function of both SNPs and it is uncertain whether 
or not the rs9582036 and rs9554320 variants can be 
used as genetic predictors for the outcome of sunitinib 
treatment. In this study, we aimed to assess the role of 
the two VEGFR1 SNPs rs9582036 and rs9554320 with 
regard to their association with sunitinib efficacy in three 
independent well-characterized cohorts of mRCC patients. 
Moreover, we performed a meta-analysis including all the 
available data (n=564 mRCC patients) on the possible 
association of both SNPs with sunitinib efficacy in mRCC 
patients.
RESULTS
Patient characteristics of the three cohorts are 
summarized in Table 1. The median age in the SUTOX, 
SOGUG and CCF cohort was 60, 64 and 61 years, 
respectively. More than 66% of included patients were 
male and the majority (> 94%) of patients were Caucasian. 
The median follow-up was 50 months for SUTOX, 
52 months for CCF and 40 months for SOGUG cohort. 
The call rates of genotyping were higher than 95% in the 
three cohorts. There were no significant deviations from 
Hardy-Weinberg equilibrium (P>0.05). The minor allele 
frequency (MAF) of rs9582036 in the three cohorts and 
MAF of rs9554320 in the SUTOX and CCF cohorts were 
comparable with the data of HapMap-CEU in dbSNP 
(Table 2). However, the MAF of rs9554320 in the SOGUG 
cohort was significantly lower than that of HapMap-CEU 
in dbSNP (P=0.013).
Replication cohort
We analysed the association of both SNPs with 
sunitinib PFS and OS in SUTOX, CCF and SOGUG 
cohorts. VEGFR1 rs9582036 and rs9554320 showed 
similar associations with PFS in the CCF cohort as in 
previous studies. In the Kaplan-Meier analysis, patients 
with the variant CC genotype of rs9582036 from the CCF 
cohort had a dramatically shorter median PFS compared 
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to patients with an AA/AC genotype (16.8 months 
versus 35.9 months, P=0.047). In the multivariate Cox-
regression analysis corrected for age, gender and Heng 
prognostic risk group, rs9582036 and rs9554320 remained 
significantly associated with PFS in the CCF cohort (HR: 
0.254, 95%CI: 0.092-0.703; P=0.008 and HR: 0.430, 95% 
CI: 0.200-0.927; P=0.031, respectively). No significant 
difference in PFS was observed in the SUTOX and 
SOGUG cohorts for VEGFR1 rs9582036 or rs9554320. 
No significant association of both SNPs with OS was 
found in the three cohorts (Table 3).
Meta-analysis
Data from the present study and the two previous 
reports [17, 18] were extracted and pooled to evaluate 
the effect of VEGFR1 rs9582036 and rs9554320 on 
sunitinib PFS and OS. In the total population (n=564), the 
association of rs9582036 with PFS (HR: 0.60; 95%CI: 
0.34-1.05; P=0.08; Figure 1) or OS (HR: 0.51; 95%CI: 
0.26-1.02; P=0.06; Figure 2) did not reach the threshold 
for statistical significance, nor did the association of 
rs9554320 with sunitinib PFS (HR: 0.73; 95%CI: 
Table 1: Patients characteristics from two published reports and three current cohorts
Characteristics Beuselinck [18] Dornbosch [17] SUTOX CCF SOGUG
Number of patients 157 121 124 74 88
Median age at sunitinib start 
(years) 59
a 59b 60 61 64
Male 113 (72%) 95 (79%) 82 (66%) 51 (69%) 61 (69%)
Caucasian NA 121 (100%) 116 (94%) 73 (99%) 86 (98%)
Prior treatment NA 5 (4%) 28 (23%) 22 (30%) 0
 Cytokines NA 0 25 15 0
 Sorafenib NA 5 1 5 0
 Other therapies NA 0 2 2 0
Metastasis
 Lung 117 (75%) NA 82 (66%) 44 (60%) 61 (69%)
 Liver 29 (18%) NA 31 (25%) 6 (8%) 13 (15%)
 Bone 57 (36%) NA 39 (32%) 19 (26%) 23 (26%)
 Brain 11 (7%) NA 3 (2%) 9 (12%) 2 (2%)
 Mean number of 
metastases
2.31 NA 2.24 1.80 1.98
Risk group*
 Favourable 30 (19%) NA 25 (20%) 28 (38%) 10 (11%)
 Intermediate 95 (64%) NA 66 (53%) 39 (53%) 57 (65%)
 Poor 29 (20%) NA 33 (27%) 7 (10%) 21 (24%)
Median follow-up (month) 77 25 50 52 40
Median TTP/PFS (month) 12 14 16 33 17
Median OS (month) 27 25 23 53 27
a Mean age at initial diagnosis; b Median age at surgery; *Risk group by Beuselinck et al. was categorized by the 
International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) criteria, while SUTOX, CCF and SOGUG 
cohorts were categorized in Heng prognostic risk groups [25]. Both criteria include the same variables including poor WHO 
performance status (≥2), low haemoglobin (< lower limit of normal), high calcium (> upper limit of normal) and time from 
initial diagnosis to treatment with sunitinib (< 1 year), neutrophil count (> upper limit of normal) and thrombocytes (> 
upper limit of normal).
NA: not available; TTP: time to progression; PFS: progression-free survival; OS: overall survival; SUTOX: five medical 
centres in The Netherlands; SOGUG: Spanish Oncology Genitourinary Group medical centres including15 Spanish 
participating hospitals; CCF: Cleveland Clinic Foundation Taussig Cancer Institute.
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0.49-1.07; P=0.11; Figure 3) and OS (HR: 0.77; 95%CI: 
0.50-1.19; P=0.25; Figure 4).
DISCUSSION
Exploratory studies have suggested that VEGFR1 
rs9582036 and rs9554320 may be associated with PFS 
and OS in sunitinib-treated mRCC patients [16–18], but 
results were inconclusive. Whether these SNPs are useful 
as a predictive biomarker for sunitinib efficacy in mRCC 
patients remains an open question. The current study 
aimed to provide a conclusive answer to this question 
by replication of the analysis in three independent well-
characterized cohorts (SUTOX, CCF and SOGUG) with 
a total of 286 mRCC patients and performing a meta-
analysis of all available data (n=564 mRCC patients).
While associations of both SNPs with PFS could be 
confirmed in the CCF cohort (n=74), no correlation of both 
SNPs with PFS/OS was found in either the SUTOX or 
SOGUG cohort. In the meta-analysis of all available data 
(n=564), the association of the VEGFR1 polymorphisms 
with PFS or OS did not reach the threshold for statistical 
significance. Therefore, it can be concluded that VEGFR1 
rs9582036 and rs9554320 have a small effect on the 
prediction of sunitinib outcome in mRCC patients and thus 
have only limited use as genetic predictors of sunitinib 
efficacy in this disease.
In recent years, genotyping technology has 
developed rapidly and as a result the number of SNPs tested 
as potential markers for therapy selection has increased 
massively. However, it has been shown repeatedly that 
the findings in the discovery pharmacogenetic studies are 
difficult to replicate [20–23]. A major reason of replication 
failure is the large heterogeneity among studies. Of note, 
the data from the present and previous studies were 
collected retrospectively from various centres across 
the world and patients were not enrolled in a designated 
pharmacogenetic study. Use of observational data may 
have the disadvantage of less systematic collection of 
clinical data and a high heterogeneity among patients as 
compared to a clinical trial setting. However, the cohorts 
in the current study were all well characterized. Further, 
the observational data may be better representative for the 
real world clinical practice.
Due to daily clinical practice, inclusion and 
exclusion criteria were not as strict as in a clinical trial 
setting, resulting in different proportions of patients 
with prior treatment among the five cohorts. It has been 
mentioned by Beuselinck et al. that 23% of patients 
received immunotherapy prior to sunitinib [16, 18]. 
Dornbusch et al. have included 4% of patients treated 
with sorafenib before sunitinib [17]. In the present 
study, 28 (23%) and 22 (30%) patients from SUTOX 
and CCF cohorts received prior treatments, including 
immunotherapy (n=25 and 15, respectively), sorafenib 
(n=1and 5, respectively) or other (n=2 and 2, respectively). 
All patients from the SOGUG cohort were treated with 
sunitinib first-line. Obviously, prior treatments can 
influence the efficacy of subsequent therapy. However, 
as second-line therapy after cytokine failure, sunitinib 
Table 2: The minor allele frequency of VEGFR1 rs9582036 and rs9554320
SNPs Genotype SUTOX
(n=124)
CCF
(n=74)
SOGUG
(n=88)
Beuselinck 
[18]
(n=157)
Dornbusch 
[17]
(n=121)
HapMap-
CEU
(n=226)
rs9582036 AA 68 33 44 78 67 118
AC 49 36 32 64 43 84
CC 6 5 7 13 10 24
HWE
(P value) 0.45 0.24 0.73 0.98 0.48 0.13
MAF 0.248 0.311 0.277 0.292 0.260 0.292
rs9554320 CC 46 23 39 57 41 62
CA 61 40 36 68 57 122
AA 15 10 12 27 23 42
HWE
(P value) 0.45 0.26 0.43 0.39 0.713 0.19
MAF 0.373 0.411 0.345 0.404 0.426 0.456
SUTOX: five medical centres in The Netherlands; SOGUG: Spanish Oncology Genitourinary Group medical centres 
including 15 Spanish participating hospitals; CCF: Cleveland Clinic Foundation Taussig Cancer Institute; HapMap-CEU 
represents Utah residents with Northern and Western European ancestry from the CEPH (Centre d’Etude du Polymorphisme 
Humain) collection, which was collected in 1980; HWE: Hardy-Weinberg equilibrium; MAF: minor allele frequency.
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demonstrated comparable antitumor activity to sunitinib 
given as first-line [7], which makes it rational to include 
cytokine-refractory patients in the current study. The 
number of patients in the present study having received 
pre-treatment with sorafenib was small. In a post hoc 
analysis, we excluded all pre-treated patients and similar 
results were found (data not shown).
In previous studies, different covariates were used 
for multivariate analysis in each study. For example, 
Beuselinck et al. have considered International Metastatic 
Renal-Cell Carcinoma Database Consortium (IMDC) 
prognostic score as covariates [18], while Dornbusch 
et al. have corrected multivariate analyses by tumor, 
node and metastasis (TNM) stage and tumor grade [17]. 
We reanalysed our data by using the same covariates 
as the previous studies, but did not see any significant 
associations (data not shown).
DNA was mostly isolated from kidney tissues in 
both previous studies (71% in Beuselinck cohort and 
67% in Dornbosch cohort) [17, 18], whereas our DNA 
samples were all derived from whole blood, serum or 
plasma [10, 24]. Even though the sources of DNA 
Figure 1: Forest plot for association of VEGFR1 rs9582036 with sunitinib progression-free survival.
Table 3: Association analyses of VEGFR1 rs9582036 and rs9554320 with sunitinib PFS/OS in mRCC patients
Group Genotype N PFS
(month)
P1 P2 HR 95% 
CI
OS
(month)
P1 P2 HR 95%CI
rs9582036 SUTOX(n=123) AA/AC 117 15.5 0.459 0.818 1.154 0.340-3.914 22.6 0.394 0.824 1.147 0.343-3.830
CC 6 11.1 18.4
CCF
(n=74) AA/AC 69 35.9 0.047 0.008 0.254 0.092-0.703 52.5 0.869 0.321 0.528 0.150-1.862
CC 5 16.8 67.5
SOGUG
(n=83) AA/AC 76 11.7 0.501 0.535 1.369 0.507-3.700 25.6 0.524 0.533 1.472 0.437-4.954
CC 7 14.6 19.5
rs9554320 SUTOX(n=122) CC/AC 107 15.5 0.890 0.716 0.878 0.435-1.771 22.1 0.459 0.695 1.164 0.544-2.492
AA 15 16.0 22.6
CCF
(n=73) CC/AC 63 36.6 0.189 0.031 0.430 0.200-0.927 54.3 0.974 0.275 0.586 0.224-1.531
AA 10 21.4 52.5
SOGUG
(n=87) CC/AC 75 11.7 0.519 0.757 1.126 0.532-2.382 26.7 0.260 0.338 1.599 0.612-4.174
AA 12 14.6 NR
SUTOX: five medical centres in The Netherlands; SOGUG: Spanish Oncology Genitourinary Group medical centres 
including 15 Spanish participating hospitals; CCF: Cleveland Clinic Foundation Taussig Cancer Institute; P1 from log-
rank test; P2 from multiple cox regression analysis corrected by age, gender and Heng prognostic risk group [25]; NR: not 
reach; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval
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were partly different and the MAF of rs9554320 of the 
SOGUG cohort was lower than that of HapMap-CEU, 
there was no significant difference in the MAF of both 
SNPs across five cohorts. Therefore, we believe that 
differences in source of DNA in our studies as compared 
to the previous studies do not explain the failure of 
replication.
Besides the above-mentioned factors, we also 
compared the treatment regimen, follow-up period, 
period of clinical practice taken (ranging from 2004-
2015), and patients characteristics, for example, 
distribution of patients risk groups among the five 
cohorts, but did not observe major differences. Further, 
we do not have the access to the published data in 
detail and lack sufficient information on the subsequent 
treatment. The origin of inconsistencies in findings 
remains unknown. Due to the fact that the associations 
of both SNPs with sunitinib outcome were observed in 
small cohorts, the positive effects may be present by 
chance.
In conclusion, the association of VEGFR1 
rs9582036 and rs9554320 with the outcome of sunitinib 
in mRCC patients did not reach the threshold for 
statistical significance, and therefore, both genetic 
variants have limited use as biomarkers for prediction of 
sunitinib efficacy.
Figure 4: Forest plot for association of VEGFR1 rs9554320 with sunitinib overall survival.
Figure 3: Forest plot for association of VEGFR1 rs9554320 with sunitinib progression-free survival.
Figure 2: Forest plot for association of VEGFR1 rs9582036 with sunitinib overall survival.
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MATERIALS AND METHODS
Study population
Three cohorts of clear cell mRCC patients treated 
with sunitinib between the years 2004 and 2012 were 
included in this study. Patient characteristics have been 
described previously [10, 24]. The SUTOX cohort 
consisted of 124 mRCC patients from five medical centres 
in The Netherlands, the SOGUG cohort contained 88 
mRCC patients from Spanish Oncology Genitourinary 
Group (SOGUG) medical centres (15 Spanish participating 
hospitals) and the CCF cohort contained 74 mRCC 
patients from the Cleveland Clinic Foundation (CCF) 
Taussig Cancer Institute. All mRCC patients received 50 
mg, 37.5 mg or 25 mg sunitinib for at least one cycle in 
a 4-week on/2-week off schedule or a continuous dosing 
regimen. The study was conducted in accordance with 
the Declaration of Helsinki and approved by the medical 
ethics review board of all participating cohorts. Patients 
from the SOGUG and CCF cohorts provided their written 
informed consent for participation. SUTOX samples were 
anonymised by a third party according to the instructions 
stated in the Codes for Proper Use and Proper Conduct in 
the Self-Regulatory Codes of Conduct (www.federa.org) 
[10, 24].
Study endpoints
The primary endpoint PFS, was defined as the time 
in months between the first day of sunitinib treatment 
and the date of progressive disease (PD) or time of last 
follow-up according to Response Evaluation Criteria 
in Solid Tumours (RECIST, v.1.0 or v1.1). Secondary 
endpoint was OS, which was measured from the first day 
of sunitinib treatment until death or time of last follow-up 
[10, 24].
Genotyping
Genomic DNA was extracted from whole blood, 
serum, plasma or peripheral blood mononuclear cell 
samples [10, 24]. Two VEGFR1 SNPs rs9582036 A>C 
and rs9554320 C>A were genotyped using Taqman 
probes (Applied Biosystems, Nieuwerkerk aan den IJssel, 
the Netherlands) on the LightCycler 480 (LC480) Real-
Time PCR Instrument (Roche Applied Science, Almere, 
The Netherlands) in SUTOX and CCF samples, and 
using KASPar SNP genotyping system (Kbiosciences, 
Hoddesdon, UK) and the sequence Detection System 
7900HT (Applied Biosystems, Foster City, CA, USA) in 
SOGUG samples. Cross validation between assays was 
described in our previous studies and confirmed analytical 
validity [10, 24].
Statistical analysis
Hardy-Weinberg equilibrium test was performed 
for both SNPs in each cohort. Survival analyses of PFS 
and OS were assessed by Kaplan-Meier method using log-
rank test. The associations of both SNPs with sunitinib 
PFS and OS were tested in each replication cohort using 
multivariate Cox-regression model. Hazard ratio (HR) 
and 95%CI for each SNP in each cohort was estimated 
by SPSS Statistical Package for Windows (version 23 
Armonk, NY: IBM Corp). Because the present study is a 
replication study, the recessive genetic model was assumed 
in order to keep consistency with previously published 
studies. Well-established covariates age, gender and Heng 
prognostic risk group [25] were included as covariates in 
the multivariate model for PFS and OS.
Due to the lack of HR from multivariate analysis 
for validation cohort (n=69) from Beuselinck et al, only 
pooled cohort (n=157) was included in the meta-analysis. 
The estimated HR and 95%CI from the present study and 
previous reports [17, 18] were pooled into a meta-analysis 
using the Review Manager software (RevMan, version 
5.3). Heterogeneity of effects among the individual 
cohorts was assessed using the I2 index of heterogeneity 
and by Cochran’s Q statistic. The random effect model was 
used for meta-analysis in all cases, because when studies 
were gathered from the published literature, the random 
effects model is generally a more plausible match [26]. 
The Z test was used to determine the significance of the 
pooled HR. Missing data were kept missing except those 
used for evaluation of Heng prognostic risk group, which 
were replaced by single imputation. To test this action, the 
multivariate analyses were performed with and without 
the replacement of the patients with missing factors in 
the Heng prognostic risk group. Similar results were 
generated, indicating that the replacement was legitimate.
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